BON Announces Revolutionary Postbiotic Blood Sugar Solution Nears Patent Launch

Rhea-AI Summary

Bon Natural Life (Nasdaq: BON) has announced the upcoming launch of a revolutionary patent for a natural postbiotic ingredient targeting blood sugar regulation. The food-derived formula demonstrates significant efficacy in glycemic management, reducing post-meal blood sugar spikes by 15-30% within 1-3 hours when consumed 10-30 minutes before meals.

The solution outperforms existing market alternatives while offering key advantages including food safety and ease of use, factors contributing to high user compliance. The company is pursuing an aggressive global patent protection strategy over the next two years across major markets, aiming to secure their position in the metabolic health sector.

Positive

• Innovative product shows 15-30% reduction in post-meal blood sugar spikes
• Product outperforms existing market solutions
• Global patent protection strategy to secure market position
• Product features promote high user adherence

Negative

• No specific launch timeline provided
• Patent approvals still pending across major markets

News Market Reaction

-25.78%

1 alert

-25.78% News Effect

On the day this news was published, BON declined 25.78%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

XI’AN, China, March 20, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar is gearing up for release. The Company has engineered a food-derived postbiotic formula for glycemic management, slated to hit shelves in the near term. When taken 10-30 minutes before meals, this breakthrough product delivers targeted control over post-meal glucose spikes, cutting blood sugar surges by 15-30% within the critical 1-3 hour window after eating-proven through rigorous testing.

Early data shows its efficacy not only rivals but outperforms leading products already dominating the market. Beyond its precision, the formula boasts a unique edge: It’s food-safe, easy to use, and designed for seamless integration into daily routines-key factors driving high user adherence. With these advantages, the solution is poised to disrupt the post-meal blood sugar control sector and capture significant market share.

Yongwei Hu, Chairman of the Company, said "Backed by a robust IP strategy, the Company is aggressively pursuing global patent protection. Over the next two years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal."

About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR
Email: bonnatural@appchem.cn

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

FAQ

What is the effectiveness of BON's new blood sugar control solution?

The solution reduces post-meal blood sugar spikes by 15-30% when taken 10-30 minutes before meals, with effects lasting 1-3 hours after eating.

How does BON's postbiotic blood sugar formula compare to existing market solutions?

According to early data, BON's formula outperforms leading products currently dominating the market while offering additional benefits of food safety and ease of use.

What is BON's patent strategy for their new blood sugar management solution?

BON plans to secure global patent approvals across major markets over the next two years to protect their technology and ensure long-term market dominance.

When will BON's new postbiotic blood sugar management product be available?

The product is described as being in final stages and 'slated to hit shelves in the near term,' though no specific launch date is provided.